APA (7th ed.) Citation

PR, P., D, G., T, W., Y, O., M, M., S, K., . . . SM, S. (2022). HALT-D: A randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast cancer research and treatment, 196(3), 571. https://doi.org/10.1007/s10549-022-06743-9

Chicago Style (17th ed.) Citation

PR, Pohlmann, et al. "HALT-D: A Randomized Open-label Phase II Study of Crofelemer for the Prevention of Chemotherapy-induced Diarrhea in Patients with HER2-positive Breast Cancer Receiving Trastuzumab, Pertuzumab, and a Taxane." Breast Cancer Research and Treatment 196, no. 3 (2022): 571. https://doi.org/10.1007/s10549-022-06743-9.

MLA (9th ed.) Citation

PR, Pohlmann, et al. "HALT-D: A Randomized Open-label Phase II Study of Crofelemer for the Prevention of Chemotherapy-induced Diarrhea in Patients with HER2-positive Breast Cancer Receiving Trastuzumab, Pertuzumab, and a Taxane." Breast Cancer Research and Treatment, vol. 196, no. 3, 2022, p. 571, https://doi.org/10.1007/s10549-022-06743-9.